Marseille

• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 4 2024-04-08 Mantle Cell Lymphoma (MCL)
• Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international … Recruiting
  2023-508153-12-00 5 2024-03-26 Hospital-acquired pneumonia
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer
• Open-Label Extension of EDG-5506 in Participants with Becker Muscular Dystrophy Recruiting
  2023-506231-15-00 4 2024-02-22 Becker Muscular Dystrophy
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Recruiting
  2022-501890-38-00 4 2024-02-16 acute ischemic stroke
• ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc … Recruiting
  2023-505486-92-00 4 2024-02-09 Small bowel adenocarcinoma
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• Study assessing the efficacy of etoposide free chemotherapy plus durvalumab in first line extensive disease Small Cell Lung Cancer Recruiting
  2023-504670-38-00 4 2023-11-17 Extensive disease Small Cell Lung Cancer
• A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicit … Recruiting
  2022-501882-29-00 5 2023-11-03 Generalized Myasthenia Gravis (gMG)
• VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting
  2022-503055-26-00 9 2023-10-30 Unresectable recurrent or metastatic HPV16 (Human Papilloma Virus) pos
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 4 2023-10-17 Large cell neuroendocrine carcinoma
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors Recruiting
  2022-502654-14-00 4 2023-09-11 Endometrial cancer
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca … Recruiting
  2022-501703-27-00 5 2023-07-05 Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
• Phase 1/2 Open Label solid tumour Safety and Tolerability study in Pediatric and Young Adult subjects. Recruiting
  2023-506464-14-00 9 2023-06-29 Advanced solid tumors
• A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly … Recruiting
  2022-500275-31-00 5 2023-06-20 Haemophilia A
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of … Recruiting
  2023-504254-35-00 7 2023-06-20 Unresectable locally advanced or metastatic solid tumors: • Clear cell
• A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease Recruiting
  2022-500718-24-00 5 2023-06-09 IgG4-Related Disease
• Treatment of heart and blood vessel disease (cardiovascular disease) with low dose blood thinner (low dose rivaroxaban) in people with advan … Recruiting
  2024-512483-59-00 5 2023-06-09 Improvement of cardiovascular outcomes in patients with advanced chron
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS … Recruiting
  2022-500479-29-00 10 2023-03-28 International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte

Showing 241–264 of 1,485 trials